Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/72035
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma |
Author: | Piekarz, R. Frye, R. Prince, H. Kirschbaum, M. Zain, J. Allen, S. Jaffe, E. Ling, A. Turner, M. Peer, C. Figg, W. Steinberg, S. Smith, S. Joske, D. Lewis, I. Hutchins, L. Craig, M. Fojo, A. Wright, J. Bates, S. |
Citation: | Blood, 2011; 117(22):5827-5834 |
Publisher: | Amer Soc Hematology |
Issue Date: | 2011 |
ISSN: | 0006-4971 1528-0020 |
Statement of Responsibility: | Richard L. Piekarz, Robin Frye, H. Miles Prince, Mark H. Kirschbaum, Jasmine Zain, Steven L. Allen, Elaine S. Jaffe, Alexander Ling, Maria Turner, Cody J. Peer, William D. Figg, Seth M. Steinberg, Sonali Smith, David Joske, Ian Lewis, Laura Hutchins, Michael Craig, A. Tito Fojo, John J. Wright and Susan E. Bates |
Abstract: | Romidepsin (depsipeptide or FK228) is a histone deacetylase inhibitor, one of a new class of agents active in T-cell lymphoma. A phase 2 trial was conducted in cutaneous (CTCL) and peripheral (PTCL) T-cell lymphoma. Major and durable responses in CTCL supported the approval of romidepsin for CTCL. Forty-seven patients with PTCL of various subtypes including PTCL NOS, angioimmunoblastic, ALK-negative anaplastic large cell lymphoma, and enteropathy-associated Tcell lymphoma were enrolled. All patients had received prior therapy with a median of 3 previous treatments (range 1-11); 18 (38%) had undergone stem-cell transplant. All patients were evaluated for toxicity; 2 patients discovered to be ineligible were excluded from response assessment. Common toxicities were nausea, fatigue, and transient thrombocytopenia and granulocytopenia. Complete responses were observed in 8 and partial responses in 9 of 45 patients, for an overall response rate of 38% (95% confidence interval 24%-53%). The median duration of overall response was 8.9 months (range 2-74). Responses were observed in various subtypes, with 6 responses among the 18 patients with prior stemcell transplant. The histone deacetylase inhibitor romidepsin has single agent clinical activity associated with durable responses in patients with relapsed PTCL. This study has been registered at clinical trials. gov as NCT00007345. |
Keywords: | Humans Lymphoma, T-Cell, Cutaneous Lymphoma, T-Cell, Peripheral Skin Neoplasms Disease Progression Depsipeptides Antibiotics, Antineoplastic Treatment Outcome Remission Induction Survival Rate Tissue Distribution Adult Aged Aged, 80 and over Middle Aged Female Male Lymphoma, Large-Cell, Anaplastic |
Rights: | Copyright © 2011 by American Society of Hematology |
DOI: | 10.1182/blood-2010-10-312603 |
Published version: | http://dx.doi.org/10.1182/blood-2010-10-312603 |
Appears in Collections: | Aurora harvest Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.